Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Brainify.AI logo — AI biomarker platform for a novel treatment developed for de...

Brainify.AI

AI biomarker platform for a novel treatment developed for depression. Part of J&J Jlabs and Merck DSS.

Founded 2021 United States New York, United States 11 employees Pre-Seed Total: $1.60M AI, Health Care +2

General Information

Company Name Brainify.AI
Founded Year 2021
Location United States New York, United States
Employees 11
Industries AI, Health Care, Pharmaceutical +1
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with Brainify.AI. To contact Brainify.AI, visit brainify.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Brainify.AI compare?

A PDF of Brainify.AI and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Brainify.AI soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Brainify.AI

Brainify.AI, founded in 2021, is revolutionizing the pharmaceutical landscape with its cutting-edge AI biomarker platform. This innovation, designed specifically for the development of novel treatments for depression, is positioned to enhance the likelihood of new treatment approvals and boost drug efficacy. Positioned uniquely at the crossroads of multiple burgeoning industries — AI, Health Care, Pharmaceutical, and Machine Learning — Brainify.AI operates out of the United States.

Endorsed by influential partners, Brainify.AI is a proud member of J&J Jlabs and Merck DSS, and is bolstered by investments from prominent backers including Merck GHI Fund, Northpond, and Kodori VC. The company recently secured a $1.00 million Pre Seed Round investment as of January 10, 2023, showcasing robust confidence in its vision and potential within the competitive realm of depression treatment solutions.

Business keywords: AI biomarker platform, depression treatment, drug development, AI/ML, EEG biomarker, clinical trials, R&D efficiency, patient outcomes, PlaceboInsight AI, TherapyInsight AI, CleanSpectrum AI, pharmaceutical innovation, investment backed, clinical data analysis

Services & Products

Developing and applying AI models for precision neuroscience
analyzing brain data to identify EEG biomarkers for neurological disorders and drug development.

Target Customers

Clinics pharmaceutical companies research institutions and professionals in the healthcare and neuroscience fields.

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round $1.00M -
10 Jan 2023
Pre Seed Round $100.00K -
01 Nov 2022
Pre Seed Round $100.00K -
10 Aug 2022
Pre Seed Round $100.00K -
01 Feb 2022
Pre Seed Round $100.00K -
01 Dec 2021
Pre Seed Round $200.00K -
16 Apr 2021

Brainify.AI Alternatives & Competitors

View All Alternatives
Brainify.AI vs
Ignota Labs
Ignota Labs United Kingdom

Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hop...

Seed
18 employees
AI, Biotechnology
Brainify.AI vs
RayzeBio
RayzeBio United States

Targeted innovative radiopharmaceuticals for cancer

Acquired
258 employees
Biotechnology, Health Care
Brainify.AI vs
OncXerna Therapeutics
OncXerna Therapeutics United States

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel,...

Venture round
8 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Brainify.AI

AI biomarker platform for a novel treatment developed for depression. Part of J&J Jlabs and Merck DSS.
Brainify.AI was founded in 2021.
Brainify.AI is headquartered in New York, United States.
Brainify.AI operates in AI, Health Care, Pharmaceutical and Machine Learning. Its work centres on AI biomarker platform, depression treatment, drug development and AI/ML. Its customers include Clinics, pharmaceutical companies and research institutions.
Brainify.AI has approximately 11 employees.
Brainify.AI has completed 6 funding rounds, raising a total of $1.60M. The latest funding stage is Pre-Seed.
Brainify.AI offers: Developing and applying AI models for precision neuroscience, analyzing brain data to identify EEG biomarkers for neurological disorders and drug development..
Top alternatives and competitors to Brainify.AI include Ignota Labs, RayzeBio, OncXerna Therapeutics , BeBetter Med, Partex.AI Technology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Brainify.AI and Ignota Labs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Brainify.AI, https://bouncewatch.com/company/brainifyai, updated 14 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout